Plasma Proteomics: optimized experimental design in cardiovascular disease

Atherothrombosis is the leading cause of death in the Western world. The pathophysiology of thrombosis is still unknown because its mechanisms are a network of molecules with multiple relationships among them. The use of new proteomic methodologies in the study of cardiovascular disease has generated new data of great interest and even the description of new biomarkers with diagnostic value. The challenge of working with biological samples such as plasma/serum, urine, saliva, CSF... is facing a dynamic range of several orders of magnitude (12 logarithmic scales in the case of plasma). Although there are robust analytical platforms and technologically advanced, it is a challenge to develop a workflow that allows both reduce the complexity of these samples and not lose any information. The advanced techniques of quantitative proteomics (SELDI-TOF, LC-MALDI-TOF/TOF, 2D-DIGE, etc) could address these samples but you need a refinement of them to gain access to known as deep proteome .